Madrigal Pharmaceuticals (MDGL) Q2 2026 earnings — TrendMatrix coverage
Reported
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Full disclosure
Key numbers
- Adjusted EPS
- -$1.99
- Estimate
- -$2.23
- Surprise
- +10.8%
- Revenue (period 2026-06-30)
- $364.3M
- Score at report (before → after)
- 5.8 → 5.9/10
Revenue source: xbrl.
How the report landed
Madrigal Pharmaceuticals (MDGL) reported a narrower loss than forecast — adjusted EPS of -$1.99 against the -$2.23 estimate (a 10.8% beat on a still-unprofitable quarter). TrendMatrix's engine moved from Buy (Wait) (5.8/10) to Hold at 5.9/10 after the report.
Where TrendMatrix's rating stands now
TrendMatrix currently rates MDGL Sell at 5.9/10.
2 of the last 4 quarters beat the estimate; this quarter's +10.8% surprise compares with a -65.9% four-quarter average. Next scheduled report: 2026-11-04.
What supports the rating
- Sector modifier (Healthcare): +0.5
- Strong growth profile
What argues against it
- Concentration risk — Product: Rezdiffra
- V7 low-quality RISK_OFF penalty: -0.5 (Q=4.2)
- Consecutive earnings misses (2)
This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.
The levels TrendMatrix's engine tracks
- Current price
- $452.12
- Price target
- $613.90
- Stop
- $435.31
- Upside to target
- +35.8%
- Reward-to-risk
- 4.9:1
Risk check: RSI 9 — a level conventionally read as oversold.
Model outputs from TrendMatrix’s engine as of 2026-10-14 — shown for context, not personalized investment advice.
MDGL at TrendMatrix's latest read
Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.
- Industry
- Biotechnology
- Market cap
- $10.45B
- P/E (fwd)
- 47.0
- 52-week range
- $393.61–$615.00
- Off 52-week high
- 26.5%
- RSI (14)
- 9
- Volume vs avg
- 1.14×
- Score today
- 5.9/10